| Title: |
Use of attr cardiac amyloidosis imaging in latin america |
| Authors: |
Alexanderson-Rosas, E; Carvajal-Juarez, I; Erriest, J; Blacher-Grossman, G; Camilletti, J; Mut, F |
| Source: |
European Heart Journal - Cardiovascular Imaging ; volume 24, issue Supplement_1 ; ISSN 2047-2404 2047-2412 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2023 |
| Description: |
Funding Acknowledgements Type of funding sources: None. Background/Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is associated with high morbidity and mortality(1). Non-invasive imaging techniques and novel treatments allow for a better prognosis, but a lack of clinical awareness of the proper use of imaging delays appropriate diagnosis and management. Since 2019, when the multi-society expert consensus on recommendations for multimodality imaging in cardiac amyloidosis (2) was published, multiple international societies have also published their position (3) making imaging techniques such as nuclear medicine scintigraphy (NMS), cardiac magnetic resonance (CMR) and transthoracic echocardiogram (TTE) the methods of choice for the diagnosis of ATTR-CM. Purpose We aim to know how non-invasive imaging methods are used to diagnose ATTR-CM in Latin America (LA) Methods Anonymous online surveys were distributed digitally among clinicians across LA for two months (June-July 2021). We asked about the availability and use of non-invasive cardiac imaging techniques to diagnose ATTR-CA. The information was automatically entered into a spreadsheet for tabulation and descriptive statistical analysis (Microsoft Excel 2016). Results Surveys were collected from 82 NM centers and 406 clinicians (mainly cardiologists, 65%), with responses from professionals from 17 of the 20 LA countries. The diagnostic image most available among the respondents was NMS (100%), followed by TTE ( 86%), and the last, CMR (76%). Fig 1. All nuclear medicine centers have access to perform SPECT acquisition, but advanced technology is lacking in some areas (SPECT/CT-44%, CZT-7%). Of the available phosphonates, PYP is accessible in most centers (83%); a minority use HMPD (12%), and just four centers use MDP (5%). Regarding TTE availability, only 59% can perform advanced techniques as GLS. Something similar happens in the availability of CMR since only 42% have access to advances sequences as mapping. When we presented a clinical ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/ehjci/jead119.183 |
| Availability: |
https://doi.org/10.1093/ehjci/jead119.183; https://academic.oup.com/ehjcimaging/article-pdf/24/Supplement_1/jead119.183/50623727/jead119.183.pdf |
| Rights: |
https://academic.oup.com/pages/standard-publication-reuse-rights |
| Accession Number: |
edsbas.DCC2E72A |
| Database: |
BASE |